Shuttle Pharma appoints Christopher Cooper as interim Co-CEO to boost business activities

Shuttle Pharmaceuticals Holdings, Inc.

Christopher Cooper appointed interim Co-CEO effective March 11, 2025; focused on capital markets and business capabilities.
Dr. Anatoly Dritschilo continues as Chairman and Co-CEO overseeing scientific and clinical trial activities.
Consulting agreement with Cooper's entity pays $20,000/month for six months, 40 hours/week, with 30-day termination notice.
Cooper has 27 years of management/finance experience, raised over $100M in debt and equity for prior clients.
Company's ongoing Phase 2 trial of Ropidoxuridine for glioblastoma continues under Dritschilo's leadership.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Christopher Cooper

interim co-Chief Executive Officer

SHPH · Shuttle Pharmaceuticals Holdings, Inc.

Effective: 2025-03-11
Filed: March 12, 2025, 7:59 PM ET

On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Cooper was appointed as interim co-Chief Executive Officer at Shuttle Pharmaceuticals Holdings, Inc..

Action: appointed
Role: interim co-Chief Executive Officer

Exact text from the filing

On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).

View on SEC.gov

Shuttle Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-009922

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.